BioSpace News Archive

Drug Development

Reanalysis of Key Trial Flags Fresh Safety Concerns for Amgen’s Repatha (Updated)

Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.

January 4, 2023
·
3 min read
·
Tristan Manalac
Drug Development

Market Appears to Question Competitive Prospects of Vera’s IgAN Therapy

Vera Therapeutics’ stock crashed following the reveal of data from a Phase IIb study of atacicept in IgAN.

January 4, 2023
·
2 min read
·
Tristan Manalac
Business

Belharra Launches with $130M From Versant, Genentech to Advance Chemoproteomics Platform (Updated)

Backed by Versant and Genentech, Belharra Therapeutics launched Wednesday with $130 million in total financing to advance its novel chemoproteomics platform.

January 4, 2023
·
2 min read
·
Rosemary Scott
Drug Development

MD Anderson Delivers a Triple Punch to Pancreatic Cancer

In a recently published study, MD Anderson researchers achieved curative responses in pancreatic cancer models by targeting checkpoints in T cells and myeloid suppressor cells.

January 4, 2023
·
4 min read
·
Heather McKenzie
Business

BrainStorm Preps for Type A NurOwn Meeting, Shakes Up C-Suite

BrainStorm Cell Therapeutics appoints a new co-CEO as it prepares for a January 11th Type A meeting for ALS hopeful NurOwn.

January 4, 2023
·
3 min read
·
Heather McKenzie
Drug Development

Geron Announces Positive Phase III Data, Likely to Seek FDA Approval in MDS

Geron announced Wednesday positive topline results from the Phase III IMerge trial evaluating the telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes patients.

January 4, 2023
·
2 min read
·
Lisa Munger
Executives Reunite at JPM as Biotech Kicks Off 2023

JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.

January 4, 2023
·
5 min read
·
Gail Dutton
Business

Pharnext Strengthens its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of Quality

Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Scott Johnson as VP, Head of Quality.

January 4, 2023
·
5 min read
Business

Monica Shaw appointed CEO of Oncopeptides - Jakob Lindberg assumes position as Chief Scientific Officer

Oncopeptides AB, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, announces that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides.

January 4, 2023
·
4 min read
Biotech Bay

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

Ultragenyx Pharmaceutical Inc. today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 12:45 PM ET.

January 4, 2023
·
1 min read